Articles tagged with Metastasis
Scientists discovered that radioresistant cancer cells' invasiveness increases following radiotherapy, thanks to upregulated lysosome trafficking. The Arl8b molecule plays a key role in this process, while the BORC complex is required for its interaction with lysosomes.
The study reveals that KDM5A and PHF2 positively control the expression of pro-metastatic genes in Ewing sarcoma. These genes include L1CAM, which promotes migratory and invasive properties. The researchers identified KDM5A and PHF2 as novel disease-promoting factors and potential new targets for metastasis inhibition.
Researchers found that fluorine-18-labeled fluciclovine PET/MRI accurately identified prostate cancer lesions, suspicious lymph nodes, and detected nodal metastases not visible on conventional imaging. The technology also showed promise in evaluating response to androgen deprivation therapy.
A recent study published in Cell reveals that microglia, a type of immune cell, promote breast cancer metastasis to the brain by suppressing T-cells. The activation of VISTA checkpoint suppresses immune response, allowing cancer cells to spread and form secondary tumors.
A randomized phase II/III trial found that SBRT reduced pain in patients with spinal metastases by 35% after three months, compared to 14% for conventional radiation. Patients treated with SBRT also experienced higher satisfaction rates related to financial considerations.
Scientists identified an antibody that blocks a signaling molecule in vascular system, causing tumor lymph vessels to die and preventing metastasis. This approach may lead to new ways to block the spread of tumor cells.
A randomized phase III trial found that stereotactic radiosurgery reduces cognitive decline without compromising survival for patients with four or more brain metastases. Patients who received SRS had better preserved cognitive function compared to those who received whole-brain radiation therapy.
The study compared survival rates in patients undergoing surgery for brain metastases with conventional white light microscopy versus 5-ALA fluorescence microscopy. The results showed no significant difference in local recurrence or mortality between the two groups, but radiotherapy was strongly associated with improved survival.
Researchers have developed a new diagnostic tool that can detect cancer cells in small blood samples and connect them to their original tumor. This method has shown significant correlations between circulating tumor cells and tumor expression levels, allowing for targeted therapeutic agents to be used more accurately.
Rutgers researchers identified 16 gene markers that collaborate to cause metastatic prostate cancer, enabling the prediction of high-risk patients. These markers can help inform personalized therapy and improve outcomes for those with advanced disease.
Researchers discovered a novel mechanical mechanism of metastatic cancer cells responding to varying substrate stiffness. Metastatic breast cancer cells adapt their tension and viscoelasticity to survive in new environments, enabling the development of diagnostic kits and drug-screening tests.
Sarah-Maria Fendt and Markus Ralser receive the EMBO Gold Medal for their pioneering work in understanding metabolic changes during cancer proliferation and metastasis formation. Their discoveries have the potential to develop more effective cancer therapies.
A study by Tampere University and the University of Oxford has identified a principle that explains how prostate cancer spreads, with implications for liquid biopsy. Researchers discovered that not all subclones spread to the entire body, and some may be confined to the prostate.
Research at NYU College of Dentistry identifies genes highly expressed in painful, metastatic oral cancers, revealing a mechanism for cancer pain. The study's findings may lead to the development of biomarkers and objective molecular tests to diagnose risk of metastasis.
A Purdue University team has developed a magnetically moving cell culturing system to evaluate the impact of mechanical forces on breast cancer cells. The technology allows for the growth of 3D cancer cells in a new tissue environment, mimicking the physiological conditions found in the lungs during breathing.
Researchers at UVA Cancer Center developed a set of metrics to evaluate care provided for brain metastases, aiming to enhance treatment decisions and coordination. The findings, published in JCO Oncology Practice, will help hospitals improve their interdisciplinary treatment programs.
Research at the European Breast Cancer Conference highlights a significant difference in survival rates between breast cancers detected during screening and those detected in the interval between screenings. Screen-detected cancers have higher eight-year distant metastasis-free interval rates, even among high-risk tumours.
A new method for identifying sentinel lymph nodes (SLNs) in breast cancer uses photoacoustic microscopy and CD44 and SR-B1 dual-targeting nanoparticles. The technique distinguishes between metastatic SLNs and inflamed LNs, providing a potential solution for reducing complications during surgery.
Researchers found that asymptomatic breast cancer patients with brain metastases had fewer and smaller tumors, received less aggressive treatment, and lived longer than those who developed symptoms. The study suggests that early detection of brain metastases could improve survival rates for these patients.
Scientists have identified enzymes ASB13 and USB20 that regulate the recycling of a dangerous protein called SNAI2, which helps cancers metastasize. Targeting these enzymes may provide a way to control SNAI2's aggressiveness and prevent cancer progression.
A new study by City of Hope researchers found that Black patients are less likely to receive chemotherapy and have a higher chance of death compared to white patients with advanced colorectal cancer. The study suggests that all patients with liver metastases should be evaluated for surgery, regardless of race.
A study by Professor Nicola Aceto's research group at the University of Basel found that a lack of oxygen in tumors triggers the formation of metastases. The team discovered that cancer cells with insufficient oxygen leave the primary tumor to migrate and form new tissues.
Researchers found that EMT promotes successful rounding and cell division in tumor cells, making them stiffer while surrounding non-dividing cells become softer. The study suggests a new direction for understanding how EMT influences cancer cell behavior.
Researchers identified EphA2 as a key driver of metastasis and BRAF-MEK inhibitor resistance in melanoma. The study found that the noncanonical pathway of EphA2 induces an amoeboid phenotype that enhances metastatic potential.
Researchers at Johns Hopkins Kimmel Cancer Center created a 3D blood vessel model to study how cancer cells spread. They found that cancer cells can take over existing blood vessels, causing them to leak or constrict, and release tumor cells into the bloodstream.
A new combination therapy targeting breast cancer tumors in the brain has been shown to reduce tumor size and increase survival in a study with mice. The treatment, which combines vinorelbine and I-BET-762, was found to be effective in curing up to 75% of mice with brain metastases.
A new small molecule treatment reduces colon cancer metastasis by locking up cancer cells' ability to change shape and move throughout the body. The treatment cut the rate of cancer metastasis in half, according to a study published in the Proceedings of the National Academy of Sciences.
A team of researchers has identified a novel drug target, 4-hydroxyacetophenone (4-HAP), that activates a protein motor and disrupts biomechanical processes essential to cell motility. In a mouse model, targeting this protein motor reduces the metastasis of colon cancer cells.
PIM kinases promote metastatic growth by regulating actin fibre formation in the cytoskeleton, supporting PIM-targeted therapies to prevent metastasis. The study provides critical information on factors regulating cancer cell motility, essential for preventing cancer spread.
A new study reveals that melanoma cells that pass through lymph nodes pick up a protective coating, allowing them to survive high levels of oxidative stress in the blood. This coating, composed of oleic acid, protects cancer cells from ferroptosis and enables them to form distant tumors.
Scientists at Japan Advanced Institute of Science and Technology developed a novel chemotherapeutic agent using nanotechnology and genetic engineering. The agent, called photothermogenetics, targets cancer cells with high potential and effectively regulates cancer stemness.
Researchers have discovered genes that facilitate the penetration of cancer cells into the brain, a process that complicates cancer treatment. The study highlights potential targets for therapy, including enzymes and microRNAs involved in disrupting blood-brain barrier integrity.
Researchers successfully reduced metastatic spread by using medication treatment around the time of surgery, preventing development of metastases. The study found a significant reduction in metastasis development rate in treated patients compared to those receiving a placebo.
A recent clinical trial found that aspirin use increased the risk of advanced cancer progression and early death in older adults. Aspirin was associated with a higher risk of metastasized cancer and stage 4 cancer, leading to higher mortality rates among those diagnosed with advanced solid cancers.
Researchers developed an optically induced electrokinetics (OEK) microfluidic method for label-free separation and characterization of gastric cancer cells. The new technique, published in Science Advances, achieved purity up to 71% in separating cancer cells from ascites and demonstrated rapid and non-destructive capabilities.
Deborah Lang's research aims to discover innovative treatments for melanoma by targeting molecular pathways involved in normal cell development. The grant will support her study on the role of YAP and TAZ genes in melanoma progression.
A new pathological grading system evaluates the therapeutic effect of neoadjuvant chemotherapy for metastatic lymph nodes in esophageal cancer patients. The system predicts recurrence and prognosis more accurately than conventional methods.
Researchers at Tel Aviv University found that immunotherapeutic treatment and stress-reducing measures can prevent cancer metastasis development. The critical period around tumor removal surgery is crucial for prevention, which is often overlooked in medical practice.
Researchers found that Fusobacterium nucleatum, a common mouth bacteria, can initiate cancer cell migration by sticking to and entering cancer cells using protein Fap2. This causes cancer cells to release cytokines IL-8 and CXCL1, leading to inflammation and attracting immune cells.
BRD4 protein regulates key proteins contributing to prostate cancer progression, suggesting new therapeutic target. Current treatments for castration-resistant prostate cancer are limited and focus on suppressing tumor cells' reliance on androgen receptor signaling.
Researchers discovered that cancer cells with high-affinity iron collection systems collect iron more efficiently than healthy macrophages, allowing them to survive in nutrient-deprived CSF environments. This mechanism enables LM cells to evade immune attack by limiting the supply of vital iron to patrolling macrophages.
Researchers found the AZIN1 gene associated with metastatic prostate cancer, with reduced expression leading to fewer metastases. Further investigation is needed to confirm findings in all prostate cancers.
Researchers developed a microfluidic device to study breast cancer cells' invasion process, identifying 244 different genes that enable invasive cells. The tool mimics human tissue environments, offering new avenues for biomarkers and targeted therapies.
Researchers identify key genes driving bone cancer spread to lungs and develop a gene therapy approach that stops the spread in mice. The breakthrough could lead to 'kinder' treatments for children with bone cancer, saving lives.
A new study using uEXPLORER technology successfully detected metastatic cancer in patients, providing high-quality images of tumor behavior. Parametric images showed improved visibility of cancer lesions detection and multi-parametric characterization of tumor metastases.
Researchers discovered that metastatic breast cancer cells can reprogram natural killer (NK) cells to stop killing cancer cells and instead aid in metastasis. This work also identifies new immunotherapy strategies to reverse this reprogramming process, offering a potential way to prevent or reduce breast cancer mortality.
Researchers at Johns Hopkins University School of Medicine discovered that breast cancer cells can alter the function of NK cells to facilitate their spread. The study suggests preventing this reprogramming might stop breast cancer from metastasizing, a major cause of death in breast cancer patients.
International laboratories joined forces to create BrMPanel, a repository of over 60 cell lines for brain metastasis research. The platform facilitates knowledge exchange and speeds up the development of effective therapies.
Moffitt researchers discovered deltaNp63 protein plays a key role in facilitating cancer spread by oscillating its expression. The protein is overexpressed in many primary tumors and metastases, and its silence is required for cancer cells to undergo EMT.
Researchers at Hokkaido University found that inflammatory changes in tumors caused by chemotherapy trigger drug resistance in blood vessels, resulting in poorer cancer outcomes. The team also discovered a treatment strategy involving the combination of an ABCB1 inhibitor and anticancer drugs to overcome this resistance.
A new radiotracer, 68Ga-DOTA-JR11, has shown excellent imaging performance in detecting liver metastases and providing important information to guide treatment. The study found that 68Ga-DOTA-JR11 performed better than 68Ga-DOTATATE PET/CT in detecting liver lesions, with a higher tumor-to-background ratio.
A single-center retrospective study of 282 patients with early or locally advanced lung adenocarcinoma found that EGFR-mutated lung cancer had increased rates of metastatic recurrence. Early identification of these recurrences is crucial, given the improved post-relapse survival observed in this population.
A scalable 'lab-on-a-chip' device detects early and advanced breast cancer in plasma samples with high accuracy, overcoming current diagnostic limitations. The EV-CLUE chip's noninvasive method shows promise for improving cancer detection and monitoring.
Researchers report a case of hyperprogression in metastatic renal cell carcinoma patients treated with immunotherapy combinations, highlighting the need for biomarker development and treatment strategies. Cabozantinib shows promise in controlling hyperprogression, but clinical trials are needed to identify optimal approaches.
Scientists at Sanford Burnham Prebys Medical Discovery Institute have shown that a protein called Slug regulates cell movement and can be inhibited to suppress pancreatic cancer metastasis. The study also identified two druggable targets, ERK and eIF2 alpha, which hold promise as treatments for the deadly disease.
Scientists discover that nicotine, found in tobacco, promotes the spread of non-small-cell lung cancer cells into the brain. Researchers identify parthenolide as a potential treatment option to prevent brain metastasis.
Researchers found that continued nicotine use promotes brain metastasis in lung cancer patients, who often struggle to quit due to nicotine addiction. Parthenolide, a compound from the herb Feverfew, blocks this effect and may prevent brain tumors, offering new hope for treatment.
The largest ever study of radiosurgery for brain metastases from small cell lung cancer has been published in JAMA Oncology. The analysis found that patients treated with first-line stereotactic radiosurgery (SRS) had a median overall survival of 8.5 months, compared to 6.2 months for those treated with whole-brain radiation (WBRT). Ad...
A study published in Oncotarget found that T-DM1 significantly improves response rates and median progression-free survival in patients with HER2 positive metastatic breast cancer. This suggests a preferred second-line choice for T-DM1 over trastuzumab emtansine.
Researchers at Tulane University discovered a way to inhibit aggressive triple negative breast cancer by targeting the TRAF3IP2 gene. Suppressing this gene suppresses tumor growth and metastasis, while silencing another gene, Rab27a, only delays tumor growth but not metastasis.